236 related articles for article (PubMed ID: 37379135)
61. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
62. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
[TBL] [Abstract][Full Text] [Related]
63. Methotrexate for maintenance of remission in ulcerative colitis.
Wang Y; MacDonald JK; Vandermeer B; Griffiths AM; El-Matary W
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007560. PubMed ID: 26263042
[TBL] [Abstract][Full Text] [Related]
64. Probiotics for induction of remission in ulcerative colitis.
Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795
[TBL] [Abstract][Full Text] [Related]
65. Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.
Johnson T; Steere B; Zhang P; Zang Y; Higgs R; Milch C; Reinisch W; Panés J; Huang K; D'Haens G; Krishnan V
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00630. PubMed ID: 37594044
[TBL] [Abstract][Full Text] [Related]
66. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG; Sands BE; Sandborn WJ; Germinaro M; Vetter M; Shao J; Sheng S; Johanns J; Panés J;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):307-320. PubMed ID: 36738762
[TBL] [Abstract][Full Text] [Related]
67. Probiotics for maintenance of remission in ulcerative colitis.
Iheozor-Ejiofor Z; Kaur L; Gordon M; Baines PA; Sinopoulou V; Akobeng AK
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD007443. PubMed ID: 32128794
[TBL] [Abstract][Full Text] [Related]
68. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L; Allegretti JR; Rubin DT; Bressler B; Germinaro M; Huang KG; Shipitofsky N; Zhang H; Wilson R; Han C; Feagan BG; Sandborn WJ; Panés J; Hisamatsu T; Lichtenstein GR; Sands BE; Dignass A;
Gastroenterology; 2023 Dec; 165(6):1443-1457. PubMed ID: 37659673
[TBL] [Abstract][Full Text] [Related]
69. Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial.
Zhang S; Chen B; Wang B; Chen H; Li Y; Cao Q; Zhong J; Shieh MJ; Ran Z; Tang T; Yang M; Xu B; Wang Q; Liu Y; Ma L; Wang X; Zhang N; Zhang S; Guo W; Huang L; Schreiber S; Chen M
JAMA; 2023 Mar; 329(9):725-734. PubMed ID: 36881032
[TBL] [Abstract][Full Text] [Related]
70. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Panés J; Colombel JF; D'Haens GR; Schreiber S; Panaccione R; Peyrin-Biroulet L; Loftus EV; Danese S; Tanida S; Okuyama Y; Louis E; Armuzzi A; Ferrante M; Vogelsang H; Hibi T; Watanabe M; Lefebvre J; Finney-Hayward T; Sanchez Gonzalez Y; Doan TT; Mostafa NM; Ikeda K; Xie W; Huang B; Petersson J; Kalabic J; Robinson AM; Sandborn WJ
Gastroenterology; 2022 Jun; 162(7):1891-1910. PubMed ID: 35227777
[TBL] [Abstract][Full Text] [Related]
71. Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P; Sandborn WJ; Feagan BG; Reinisch W; Olson A; Johanns J; Travers S; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
N Engl J Med; 2005 Dec; 353(23):2462-76. PubMed ID: 16339095
[TBL] [Abstract][Full Text] [Related]
72. Type I interferons for induction of remission in ulcerative colitis.
Wang Y; MacDonald JK; Benchimol EI; Griffiths AM; Steinhart AH; Panaccione R; Seow CH
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD006790. PubMed ID: 26368001
[TBL] [Abstract][Full Text] [Related]
73. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
74. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
75. Transdermal nicotine for induction of remission in ulcerative colitis.
McGrath J; McDonald JW; Macdonald JK
Cochrane Database Syst Rev; 2004 Oct; (4):CD004722. PubMed ID: 15495126
[TBL] [Abstract][Full Text] [Related]
76. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
[TBL] [Abstract][Full Text] [Related]
77. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
[TBL] [Abstract][Full Text] [Related]
78. Curcumin for maintenance of remission in ulcerative colitis.
Kumar S; Ahuja V; Sankar MJ; Kumar A; Moss AC
Cochrane Database Syst Rev; 2012 Oct; 10():CD008424. PubMed ID: 23076948
[TBL] [Abstract][Full Text] [Related]
79. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
[TBL] [Abstract][Full Text] [Related]
80. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
Hanzel J; Ma C; Jairath V
Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
